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STATINS FOR EVERYONE?
Huffman and colleagues’ response to Abramson and
colleagues’ article on statins in low risk people
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The BMJ Analysis article on statins in low risk people stated,
“the evidence does not show that the benefits of statins in low
risk patients outweigh the harms and that the advice for
treatment of this group should not be changed.”1 It criticises our
Cochrane systematic review on statins for the primary prevention
of cardiovascular disease for not coming to the same conclusion.2
Readers of the BMJ may be interested in our views on their
arguments.
This article predated by three weeks the publication of the 2013
American College of Cardiology/American Heart Association
(ACC/AHA) cholesterol treatment guidelines (12 November
2013), but statements were made about “proposed standards”
without full knowledge of these guidelines. Notably, none of
the authors were acknowledged reviewers of the ACC/AHA
guidelines.3
Abramson and colleagues state: “Under the proposed 2013
standards, however, no level of risk would preclude statin
therapy, raising the question whether all people over the age of
50 should be treated.” Neither the Cochrane review nor the
ACC/AHA cholesterol guidelines proposed treatment for
everyone over the age of 50 years. The ACC/AHA guidelines
recommend that initiation of moderate intensity statin treatment
be considered for patients with a predicted 10 year “hard” risk
of arteriosclerotic cardiovascular disease of 5.0% to less than
7.5%. The Cochrane review questioned the feasibility and
desirability of having to treat most people over the age of 50
years with a statin.
The authors comment that the inclusion of four additional trials
“did not substantially alter the previously documented effect of
statin therapy.” The updating of the evidence base resulted in
an expected narrowing of confidence intervals, and the addition
of the JUPITER trial added important evidence on diabetes risk.
The authors consider that for statins to have a place in primary
prevention in people in lower strata of cardiovascular disease
risk these drugs should reduce total mortality, and they estimate
a relative risk of 0.95 (95% confidence interval 0.86 to 1.04).
However, the authors included people with andwithout previous
vascular disease in this estimate. We conducted the appropriate
analysis using only low risk people (<5%; 5-10%) without
previous vascular disease (table⇓). In the lowest risk category
(<5%), the number of total deaths was small (1% of control
group participants dying over four years) and non-cardiovascular
disease causes of death exceeded deaths from cardiovascular
disease by more than 2:1. However, the risk of experiencing a
major vascular event (fatal and non-fatal) was 0.6% per year,
which was reduced by statins (relative risk 0.62, 95% CI 0.47
to 4.81; 167 events on statin v 254 events on control; similar
effect size across major coronary event, stroke, and
revascularisation) in this low risk group (fig 1 in Cholesterol
Treatment Trialists’ 2012 paper4). No strong evidence of benefit
for total mortality was seen because other causes of death make
up a greater proportion of total deaths, and it is unlikely that
taking statins influences these non-cardiovascular disease deaths.
We disagree with Abramson and colleagues’ statement that the
“best indication of the net effect of a treatment on overall health
is the total number of serious adverse events—which include
deaths from all causes, hospital admissions, prolongations of
admission, cancer, or permanent disability.” It is incorrect to
give each of these events a similar weight. Deaths, disability,
and prolongation of admission are quite different outcomes that
would not be given similar weight by most patients.5
While criticising the randomised controlled trials, the authors
use low quality evidence from observational studies to support
their statements about the hazards associated with statins, even
though the risk of bias is likely to be high in such studies. They
also conflate muscle pain (myalgias), an important side effect
of statins, with myopathy, a rare and more serious problem,
both of which warrant ongoing study. They cite studies that
identify adverse events associated with statin therapy but fail
to cite systematic reviews that show no increased risk of
psychological outcomes, fractures, acute renal failure, arthritis,
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or venous thromboembolism.6-9 The incidence of diabetes seems
to be real but is linked to the underlying risk of developing
diabetes among participants and is also associated with the
intensity of statin dose.
Finally, Abramson and colleagues set up a false dichotomy,
stating: “Rather than being compelled by guidelines to prescribe
statin therapy for people at low risk of cardiovascular disease,
doctors would provide a far greater service by explaining the
magnitude of the benefits and uncertainty about the harms of
statins together with discussion of the epidemiological evidence
showing that behavioural risk factors—including tobacco use,
lack of physical exercise, and unhealthy diet—are responsible
for 80% of cardiovascular disease.” If they (and theBMJ editors)
had awaited the publication of the 2013 ACC/AHA cholesterol
guidelines, they would have been directed to the companion
lifestyle guidelines, which aim to deal with these topics. Salient
comment on the importance of considering benefits, harms, and
alternative non-drug treatments are embedded in the relevant
section of the report. Strong evidence to support the benefits of
the type of health promotion proposed by Abramson and
colleagues in the primary prevention of cardiovascular disease
is sadly lacking.
We have outlined several flaws in Abramson and colleagues
“Analysis,” which we believe threaten its validity. The decision
for patients at low risk of cardiovascular disease to start or
continue statins for primary prevention remains under the
purview of patients and their doctors. We hope that our
Cochrane review, which will continue to be updated as further
evidence accrues, will help inform those conversations for better
decision making and better health.
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Table
Table 1| All cause mortality for low risk patients without previous cardiovascular disease in Cholesterol Treatment Trialists’ meta-analysis4
Relative risk (95% CI)No of deaths/No of patients5 year risk of major vascular event
ControlsStatin treated
1.02 (0.80 to 1.30)127/10 993129/10 862<5%
0.81 (0.70 to 0.94)391/11 207322/11 3445-10%
0.86 (0.76 to 0.98)Pooled estimate: (I2=57%)
Heterogeneity χ2=2.35 (degrees of freedom 1), P=0.125.
Test of pooled relative risk 1, Z=2.32, P=0.02.
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